INSULET CORPORATION FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $2.7B |
| Gross margin | 71.6% |
| Operating income | $473.8M |
| Net income | $247.1M |
| Diluted EPS | $3.48 |
| Cash & equivalents | — not reported |
| Total assets | $3.2B |
| Long-term debt | $930.8M |
Key takeaway
Insulet reported full-year 2025 revenue of $2.71 billion with a healthy 71.6% gross margin, reflecting continued demand for Omnipod insulin delivery systems.
🔒 4 more takeaways in the full analysis
Beneath the surface
The $123.9 million loss on extinguishment of debt is a significant one-time item that suppressed net income relative to operating income of $473.8 million, suggesting refinancing activity not obvious from headline figures.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for PODD.
Read the full analysis free Free account · 5 full analyses included · no card required